Clinical study on telbivudine in treatment of hepatitis B virus associated glomendonephritis

Objective To investigate the clinical efficacy of telbivudine in the treatment of hepatitis B virus associated glomendonephritis(HBV-GN). Methods Sixty four patients with HBV-GN in Xi'an XD Group Hospital from October, 2011 to June, 2013 were randomly divided into control(32 cases) and treatment(32 cases) groups, and all the patients were given corresponding symptomatic treatment. Patients in the control group were po administered with Lamivudine Tablets, 1 piece/time, once daily. Patients in the treatment group were po administered with Telbivudine Tablets on the basis of symptomatic treatment, 1 piece/time, once daily. After the treatment, the treatment efficacy was evaluated, while the indexes of liver and kidney were tested. Results The efficacies in the treatment and control groups were 90.63% and 68.75%, respectively, and there were differences between the two groups(P 0.05). The treatment for 6 months, after the treatment, ALT, AST, STB, BUN, Scr, and Up/cr in the two groups were significantly reduced, while GFR and Alb were elevated, and there was significant difference compared with those before the treatment in the same group(P 0.05). And these observational indexes in the treatment group were improved better than those in the control group, and there was significant difference between the two groups(P 0.05). Telbivudine had better clinical curative effect in the treatment of all kinds of HBV-GN, and total effective rate was over 75%. Telbivudine had the best treatment effect for focal periodic glomerular sclerosis and sclerosing glomerulonephritis, and the total effective rate was up to 100%. Conclusion Telbivudine has a good clinical effect in the treatment of HBV-GN and could improve disease-related indicators, which is worthy of clinical application.